![]() |
|
|
Vol. 291, Issue 2, 569-575, November 1999
Division of Basic Medical Sciences, Health Sciences Centre,
Memorial University of Newfoundland, St. John's, Newfoundland, Canada
We tested the ability of captopril treatment (50 mg/kg/day p.o.),
initiated 2 weeks before stroke or up to 5 days after stroke, to alter
the onset of stroke and death after stroke in Kyoto Wistar stroke-prone
spontaneously hypertensive rats (SHRsp). The benefits of blood pressure
and aldosterone suppression during captopril treatment were assessed.
SHRsp developed a 100% mortality rate with intracerebral
hemorrhage by 16 weeks of age. Captopril treatment, started 2 weeks
before or at the initiation of stroke, suppressed plasma aldosterone
and equally prevented mortality to a mean age of >27 weeks. Treatment
started 5 days after stroke extended the mean lifespan to >23 weeks.
The re-elevation of plasma aldosterone (via osmotic pumps to levels in
untreated SHRsp) during captopril treatment, before stroke, allowed
stroke to develop. The initiation of the latter manipulation in pre- or
poststroke captopril-treated SHRsp at a latter age (23 weeks) didn't
alter the lifespan of SHRsp (death occurred at about 28 weeks). The
antistroke effects of captopril treatment occurred without an
antihypertensive effect, weren't altered by enhancing hypertension
during treatment (with dexamethasone), and couldn't be duplicated
by antihypertensive treatment with hydralazine. Spironolactone
treatment didn't duplicate the effects of captopril. The suppression
of plasma aldosterone may retard the onset of stroke in SHRsp during
captopril treatment but likely other factors prolong life in pre- and
poststroke SHRsp receiving long-term captopril treatment. The
observation that spironolactone treatment couldn't duplicate the
effects of captopril suggests that aldosterone may facilitate stroke
through nongenomic receptor mechanisms.
This article has been cited by other articles:
![]() |
A. I. Qureshi Acute Hypertensive Response in Patients With Stroke: Pathophysiology and Management Circulation, July 8, 2008; 118(2): 176 - 187. [Full Text] [PDF] |
||||
![]() |
J. S. Smeda and J. J. McGuire Effects of Poststroke Losartan Versus Captopril Treatment on Myogenic and Endothelial Function in the Cerebrovasculature of SHRsp Stroke, May 1, 2007; 38(5): 1590 - 1596. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ngarmukos and R. J. Grekin Nontraditional aspects of aldosterone physiology Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1122 - E1127. [Abstract] [Full Text] [PDF] |
||||